Last reviewed · How we verify
RAMOSETRON HYDROCHLORIDE
At a glance
| Generic name | RAMOSETRON HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2015 |
Approved indications
Common side effects
Key clinical trials
- Analgesic Efficacy of Maxigesic in Breast Cancer Surgery (NA)
- Special Drug Use Surveillance of Irribow in Female Patients
- The Effect of Glycyrrhizin on the Occurrence of Postoperative Nausea and Vomiting (NA)
- Acupuncture for Postoperative Nausea and Vomiting in Patients Undergoing Colorectal Surgery (NA)
- The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence (PHASE2, PHASE3)
- 5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS) (NA)
- The Effect on Anxiolytics With Type of Antiemetic Agents on Postoperative Nausea and Vomiting in High Risk Patients
- Ramosetron on Late PONV (Postoperative Nausea and Vomiting) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RAMOSETRON HYDROCHLORIDE CI brief — competitive landscape report
- RAMOSETRON HYDROCHLORIDE updates RSS · CI watch RSS